Nicolas Poirier

Company: OSE Immunotherapeutics

Job title: Chief Executive Officer

Seminars:

Neoepitopes Cancer Vaccine Monotherapy Positive Efficacy Randomized Phase 3 results in Non-Small Cell Lung Cancer with Resistance to Immunotherapy 12:30 pm

Tedopi is a tumour-specific activating immunotherapy based on highly-selected and optimized tumour neoepitopes Positive clinical efficacy of Tedopi versus chemotherapy in a randomized Phase III trial in Non-Small Cell Lung Cancer in patients with secondary resistance after failure of checkpoint inhibitors: Significantly better survival: 44% overall survival at 1-year, versus 27% with chemotherapy; Significantly better…Read more

day: Day Two